VivoSeq
Other

Glabellar Frown Lines

0

Pipeline Programs↗

0

Active Trials↗

1

Companies Involved↗

Glabellar Frown Lines is an early-stage landscape with 0 programs across 1 company. The most active players are Merz Pharmaceuticals GmbH.

Intelligence

Pipeline Metrics

Competitive Density

0/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

M

Merz Pharmaceuticals GmbH

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

15

clinical trials

Completed15 · 100%

Clinical Trials

Trial Activity

15 trials

Finding of Optimal Dose for NT 201 in the Treatment of Glabellar Frown Lines
Completed·MMerz Pharmaceuticals GmbH·Phase 2·NCT00430586·191 enrolled
Safety and Efficacy of NT 201 (IncobotulinumtoxinA [Xeomin]) in the Treatment of Glabellar Frown Lines
Completed·MMerz Pharmaceuticals GmbH·Phase 3·NCT00512135·801 enrolled
The Treatment of Glabellar Frown Lines
Completed·MMerz North America, Inc.·Phase 4·NCT02096081·250 enrolled
Study to Compare 2 Botulinum Type A Toxins in the Treatment of Glabellar Frown Lines
Completed·CCroma-Pharma GmbH·Phase 2·NCT04763265·208 enrolled
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines
Completed·MMerz Pharmaceuticals GmbH·Phase 3·NCT00430963·256 enrolled
Study to Investigate the Safety and Duration of Effect of Different Botulinum Toxin A (NT 201) Dose Groups Following the Treatment of Glabellar Frown Lines
Completed·MMerz Aesthetics GmbH·Phase 2·NCT03806933·241 enrolled
Safety and Efficacy of NT 201, Free of Complexing Proteins, in the Treatment of Glabellar Frown Lines
Completed·MMerz Pharmaceuticals GmbH·Phase 3·NCT00694148·108 enrolled
Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Crows Feet) in Subjects With Moderate to Severe Upper Facial Lines
Completed·MMerz North America, Inc.·Phase 3·NCT04622254·368 enrolled
Evaluate Safety and Efficacy of a Single Treatment Cycle of EB-001 in Subjects With Glabellar Frown Lines
Completed·BBonti, Inc.·Phase 2·NCT02939326·42 enrolled
NT 201 (Xeomin®/Bocouture®) in Comparison With Clostridium Botulinum Toxin Type A in the Treatment of Glabellar Frown Lines
Completed·MMerz Pharmaceuticals GmbH·Phase 3·NCT00777803·381 enrolled
Safety and Efficacy Study of Botulinum Toxin for the Treatment of Glabellar Frown Lines
Completed·GGalderma R&D·Phase 2·NCT02236312·359 enrolled
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines
Completed·MMerz Pharmaceuticals GmbH·Phase 3·NCT00770211·271 enrolled
Safety and Efficacy Study of the Simultaneous Treatment of Upper Facial Lines (Horizontal Forehead Lines, Glabellar Frown Lines and Lateral Canthal Lines) in Subjects With Moderate to Severe Upper Facial Lines
Completed·MMerz North America, Inc.·Phase 3·NCT04594213·362 enrolled
IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Glabellar Frown Lines No. 2
Completed·MMerz Pharmaceuticals GmbH·Phase 3·NCT00770029·276 enrolled
Non-Interventional Post-Authorisation Safety Study of NUCEIVA for the Treatment of Moderate-to-Severe Glabellar Lines
Completed·EEvolus, Inc.·N/A·NCT05481931·756 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)